Emily Rehberg, MD
Pulmonary Disease · Sylacauga, ALNPI 1932218286
Payments from drug & device makers
Across 618 payments — averaging $267.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$156K
- AstraZeneca$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Sanofi$448
- Regeneron Healthcare Solutions, Inc.$354
- Amgen$337
- plus $2K from 23 others
What the payments were for
- Consulting fees$1,4801%
- Speaking & faculty fees$151,75092%
- Travel & lodging$1,1431%
- Food & beverage$10,9087%
- Education$2330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 318 | $156,378 |
| AstraZeneca | 118 | $3,813 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $1,924 |
| Sanofi | 20 | $448 |
| Regeneron Healthcare Solutions, Inc. | 21 | $354 |
| Amgen | 20 | $337 |
| Insmed, Inc. | 12 | $297 |
| Grifols USA, LLC | 14 | $294 |
| Boehringer Ingelheim | 17 | $289 |
| Genentech USA, Inc. | 9 | $201 |
| Sanofi-aventis U.S. LLC | 2 | $196 |
| Novartis | 7 | $143 |
| Pulmonx Corporation | 6 | $131 |
| United Therapeutics Corporation | 6 | $98 |
| Intuitive Surgical | 1 | $93 |
| Verona Pharma, Inc. | 3 | $75 |
| Kedrion Biopharma, Inc. | 3 | $55 |
| Mylan Specialty L.p. | 3 | $53 |
| Paratek Pharmaceuticals, Inc. | 3 | $48 |
| Shire North American Group Inc | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Pfizer | 2 | $43 |
| Philips North America LLC | 2 | $30 |
| Baxter Healthcare | 1 | $26 |
| Viatris Specialty LLC | 1 | $25 |
| Merck | 1 | $22 |
| AbbVie | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$165,515 in reported general payments places this provider in the 90th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 65 | $627,234 |
| GlassiaAlpha-1-Proteinase Inhibitor | 38 | $534,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 587 | $530,052 |
| FasenraBenralizumab | 84 | $499,094 |
| OfevNintedanib Esylate | 26 | $264,796 |
| NucalaMepolizumab | 36 | $195,224 |
| Breo ElliptaFluticasone/Vilanterol | 308 | $167,707 |
| XolairOmalizumab | 41 | $135,902 |
| TezspireTezepelumab-Ekko | 27 | $114,038 |
| Fasenra PenBenralizumab | 20 | $112,151 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $92,443 |
| Spiriva RespimatTiotropium Bromide | 80 | $68,431 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 92 | $63,389 |
| Dupixent SyringeDupilumab | 13 | $56,230 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $37,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $156,378 | $969,4211,047 claims |
| AstraZenecaFasenra, Tezspire, Breztri Aerosphere, Symbicort | $3,813 | $721,369251 claims |
| Grifols USA, LLCProlastin C | $294 | $627,23465 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,924 | $534,98138 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $289 | $378,270165 claims |
| PfizerEliquis | $43 | $34,02633 claims |
| MerckDulera | $22 | $10,83425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Sylacauga
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
- A RidgewaySheffield$434K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
- William SaliskiMontgomery$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.